Top Markets
#1 MowCat MowCat +48.41%
#2 Bermuda Shorts Bermuda Shorts +26.38%
#3 Velvet Velvet +22.97%
#4 Fake World Assets Fake World Assets +20.31%
#5 Quack AI Quack AI +18.88%
#6 Biconomy Biconomy +18.48%
#7 Derive Derive +16.72%
#8 Perle Perle +15.52%
#9 Block Street Block Street +15.33%
#10 DUSK Network DUSK Network +14.05%
Coin of the day
MowCat MowCat
Innstillinger
Språk
NORSK
Valuta
USD
Tema
Hancock Jaffe Laboratories Hancock Jaffe Laboratories

Hancock Jaffe Laboratories

HJLI
Rangering i aksjer #35033
Hancock Jaffe Laboratories, Inc. is a medical device company in its... Hancock Jaffe Laboratories, Inc. is a medical device company in its developmental stage, specializing in creating advanced tissue-based and biologic solutions. These innovations are engineered to either sustain or significantly enhance the lives of patients afflicted with cardiovascular, peripheral arterial, and venous diseases, as well as end-stage renal disease (ESRD). The firm, headquartered in Irvine, California, maintains a dedicated team of nine full-time employees. Among its key initiatives, the company is actively developing implantable bioprosthetic devices for cardiovascular applications. This includes the Bioprosthetic Heart Valve (BHV), a swine-derived heart valve designed to mimic the function of a native heart valve and provide superior performance compared to current prosthetic options. Furthermore, the company is developing a Venous Valve, another bioprosthetic device sourced from pig tissue. This valve is specifically designed for individuals suffering from chronic venous insufficiency (CVI) in the lower limbs, a condition frequently resulting from damage to leg vein valves after the formation of deep venous blood clots.
Aksjekurs
$10.38
Sist synkronisert: 2021-09-30
Markedsverdi
$4.55M
Endring (1 dag)
-1.98%
Endring (1 år)
0.00%
Land
US
Handel Hancock Jaffe Laboratories (HJLI)

Kategori

Healthcare
P/E-forhold for Hancock Jaffe Laboratories (HJLI)
P/E-forhold per 2026 TTM: 0
Ifølge Hancock Jaffe Laboratories sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/E-forhold (TTM) 0. Ved slutten av 2026 hadde selskapet en P/E på 0.
P/E-forholdshistorikk for Hancock Jaffe Laboratories fra 2026 til 2026
P/E-forhold ved slutten av hvert år
År P/E-forhold Endre
Ikke nok data for de angitte datoene.
P/E-forhold for lignende selskaper eller konkurrenter
Selskap P/E-forhold Forskjell i P/E-forhold Land
Abbott Laboratories Abbott Laboratories
Abbott Laboratories
ABT.US
 35.77 -
US
Stryker Corporation Stryker Corporation
Stryker Corporation
SYK.US
 34.86 -
US
Medtronic plc Medtronic plc
Medtronic plc
MDT.US
 21.39 -
IE
Boston Scientific Corporation Boston Scientific Corporation
Boston Scientific Corporation
BSX.US
 20.90 -
US
Edwards Lifesciences Corporation Edwards Lifesciences Corporation
Edwards Lifesciences Corporation
EW.US
 52.64 -
US
Hvordan lese en P/E-ratio?

Pris/inntjening-forholdet (P/E) måler forholdet mellom aksjekursen og inntjening per aksje.
En lav men positiv P/E indikerer høy inntjening sammenlignet med nåværende verdsettelse, og kan tyde på at selskapet er undervurdert. En høy negativ (nær 0) P/E indikerer store tap.

Selskaper med P/E over 30 eller negativ betraktes vanligvis som "vekstaksjer", hvor investorer forventer vekst eller fremtidig lønnsomhet.

Selskaper med en positiv P/E under 10 anses vanligvis som "verdiaksjer", det vil si at selskapet allerede er lønnsomt, men har begrenset vekstpotensial.